Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ENLV |
---|---|---|
09:32 ET | 100 | 1.35 |
10:01 ET | 115 | 1.35 |
10:21 ET | 100 | 1.34 |
10:44 ET | 150 | 1.3082 |
11:47 ET | 100 | 1.315 |
12:39 ET | 3900 | 1.3299 |
01:01 ET | 100 | 1.34 |
01:03 ET | 1099 | 1.335 |
01:24 ET | 100 | 1.36 |
02:18 ET | 100 | 1.36 |
03:09 ET | 175 | 1.35 |
03:59 ET | 482 | 1.36 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Enlivex Therapeutics Ltd | 28.1M | -0.9x | --- |
Biomx Inc | 27.9M | -0.6x | --- |
NanoViricides Inc | 28.4M | -3.0x | --- |
RenovoRx Inc | 27.8M | -1.6x | --- |
BioVie Inc | 27.8M | -0.5x | --- |
Viracta Therapeutics Inc | 27.5M | -0.6x | --- |
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.56 |
Book Value | $1.62 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.